

검색결과 약 4,480개 (0.53초)

## Cystic Fibrosis Agents – LiverTox – NCBI Bookshelf

<https://www.ncbi.nlm.nih.gov/books/NBK547889> - 이 페이지 번역하기

**Lumacaftor** (loo" ma kaf' tor) is a "corrector" of the CFTR and was the second agent to gain approval as **therapy** of **CF**, but only in combination with **ivacaftor**, and specifically for **patients** who are homozygous for the Phe508del (F508del) mutation in the CFTR.

## Improvement of hepatic steatosis in cystic fibrosis with ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed> ▾ 이 페이지 번역하기

D Hayes Jr 저술 - 2015 - 25회 인용 - 관련 학술자료

Improvement of **hepatic steatosis in cystic fibrosis** with **ivacaftor therapy**. ... With the development of **ivacaftor**, which corrects the gating defect of the **CF** transmembrane regulator channel, there is a potential new **therapy** available for this subgroup of the **CF patient** population.

누락된 검색어: Lumacaftor/ reduced

## Improvement of Hepatic Steatosis in Cystic Fibrosis With ...

<https://www.researchgate.net/publication/2725118...> - 이 페이지 번역하기

With the development of **ivacaftor**, which corrects the gating defect of the **CF** ... The **treatment** of liver disease, including **hepatic steatosis**, in **patients** with cystic ... also been identified for **ivacaftor** in **patients** with G551D, such as **reduced** mucus ... in sputum cultures [56], improved insulin secretion in **patients** with **CF- related** ...

## The Extra-pulmonary Effects of CFTR Modulators in Cystic ...

<https://www.atsjournals.org/doi/pdf> - 이 페이지 번역하기

1

Name of Journal: World Journal of Hepatology

Manuscript NO: 49644

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients

Kutney K *et al.* Hepatic steatosis in cystic fibrosis

Katherine Kutney, Shannon B Donnola, Chris A Flask, Rose Gubitosi-Klug, MaryAnn O’Riordan, Kimberly McBennett, Thomas J Sferra, Beth Kaminski

Abstract

BACKGROUND

Hepatic steatosis is a common form of cystic fibrosis associated liver disease (CFLD) seen in an estimated 15%-60% of patients with cystic fibrosis (CF). The pathophysiology and health implications of hepatic steatosis in cystic fibrosis remain largely unknown. In the general population, hepatic steatosis is strongly associated with insulin resistance and type 2 diabetes. Cystic fibrosis related diabetes (CFRD) impacts 40%-50% of CF adults and is characterized by both insulin insufficiency and insulin resistance. We hypothesized that patients with CFRD would have higher levels of hepatic steatosis than

Match Overview

1	Internet 13 words crawled on 28-Aug-2019 f6publishing.blob.core.windows.net	<1%
2	Internet 12 words crawled on 28-Jul-2018 www.thieme-connect.de	<1%
3	Crossref 12 words "Poster Session Abstracts", Pediatric Pulmonology, 2018	<1%
4	Internet 12 words crawled on 20-May-2016 universalium.academic.ru	<1%
5	Crossref 12 words Lisette Leeuwen, Dominic A. Fitzgerald, Kevin J. Gaskin. " ... ver Disease in Cystic Fibrosis", Paediatric Respiratory Review	<1%
6	Crossref 12 words Z.H. Hoo, M.J. Wildman, M.D. Teare. "Exploration of the ir ... pact of 'mild phenotypes' ON median age at death IN the U	<1%



Lumacaftor/ivacaftor therapy is associated with reduced hepat



All

Images

Videos

关闭取词



21,200 Results

Any time ▾

**Lumacaftor-ivacaftor** is indicated for **treatment** of **cystic fibrosis** (CF) in **patients** homozygous for the Phe-508del **cystic fibrosis** transmembrane conductance regulator (CFTR) gene mutations. In clinical trials, treated **patients** showed improved pulmonary function, **reduced** pulmonary exacerbations, and other benefits.

The safety of lumacaftor and ivacaftor for the treatment ...

[www.ncbi.nlm.nih.gov/pmc/articles/PMC6209511/](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209511/)

Was this helpful?  

The safety of lumacaftor and ivacaftor for the treatment ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209511>

**Lumacaftor-ivacaftor therapy** may be **associated** with **ocular and hepatic side effects**. Specific recommendations for monitoring are available. **Dyspnea** occurs, especially during **initiation of treatment**. Potential **drug interactions** should be evaluated in patients taking **combination therapy**. The risk benefit ratio of **lumacaftor-ivacaftor favors therapy**.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1409547>

Discussion. **Lumacaftor-ivacaftor therapy** generally had an acceptable **side-effect** profile, with more than 93% of patients completing the assigned **therapy regimen**. These data show that the combination of a **CFTR corrector** and potentiator, designed to address the underlying **cause of cystic fibrosis** by targeting CFTR,...

Cited by: 813

Author: C. E. Wainwright, J. S. Elborn, B. W. Ram...

Publish Year: 2015

Ivacaftor and Lumacaftor - National Institutes of Health

<https://livertox.nih.gov/IvacaftorLumacaftor.htm> ▾

Dec 05, 2018 · **Tezacaftor** combined with **ivacaftor** was approved for use in the United States as